The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. ##STR00001##

The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein X; Y; R.sub.1; R.sub.2; R.sub.3; R.sub.4; R.sub.5; R.sub.6; R.sub.7 and R.sub.8 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein X; Y; R.sub.1; R.sub.2; R.sub.3; R.sub.4; R.sub.5; R.sub.6; R.sub.7 and R.sub.8 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.